

The **Center for Regenerative Therapies of the TU Dresden, Germany** (CRTD; <https://tu-dresden.de/cmcb/crtid>) is a research center with currently 22 research groups and 250 employees from 30 nations. The research focus of the CRTD is on regeneration and stem cell research, with approaches ranging from basic research to application in a clinical-translational context, thereby laying the foundations for novel diagnoses and therapies. The CRTD offers exceptional state-of-the-art facilities including Good Manufacturing Practice (GMP) clean rooms for production of cellular therapeutics. The **“Advanced Cellular Therapeutics” research group (Dr. Anke Fuchs)** <https://tu-dresden.de/cmcb/crtid/forschungsgruppen/crtid-forschungsgruppen/fuchs> offers a position for an outstanding applicant with high motivation towards GMP and clinical application.

## Postdoctoral Scientist in Cellular Immunology/T cell therapy (f/m/x)

Full or part time, payment according to TVL-E13

The Postdoc position is provided through **SaxoCell** ([www.saxocell.de/en](http://www.saxocell.de/en)), a research cluster based on **personalized gene and cell therapy development**, funded by the Cluster4Future innovation initiative of the German Ministry for Education and Research (BMBF). The position is initially limited to the first of three possible project phases until 30th of June 2024.

**Chimeric antigen receptor (CAR) T cell therapy** has revolutionized the treatment of hematological cancers. The Dresden **modular adaptor CAR** approach developed in the lab of Prof. Michael Bachmann and Dr. Anja Feldmann offers superior safety and versatility by modular antigen targeting and has recently successfully reached the clinic. Within SaxoCell, we want to take a further step and apply next-generation adaptor CAR technology to **regulatory T cells (Treg)** to generate an organ-targeted suppressive product. Importantly, polyclonal Treg GMP development and therapy has already been established in Dresden by the Fuchs lab and GMP facility in cooperation with the Hematology department of the University Hospital (Prof. Martin Bornhäuser). The project will bundle our expertises and include superior tools for **genetic modifications** developed by the lab of Prof. Frank Buchholz ([www.buchholzlab.org](http://www.buchholzlab.org)) towards our vision of an **off-the-shelf suppressive cell product** to be applied in inflammatory diseases and autoimmunity. The project includes GMP-compatible upscaling of the manufacturing process in closed ATMP systems.

As key Postdoc in the Fuchs lab you will be coordinating and driving research and development within one of the main SaxoCell research projects, co-supervise 2-3 PhD students, analyze experimental results to derive logical conclusions, draft experimental procedures, trouble-shoot and optimize to ensure progress towards our vision. The ideal candidate has a strong background in cellular immunology and profound experience in T cell culture. A previous PhD thesis or Postdoc in the CAR field would be a great asset. The position is ideal to gain experience in clinical translation, regulatory affairs and working under GMP and might serve as a springboard towards both cell & gene therapy industry or a successful academic career in translational Immunology.

### Your profile:

- PhD in life sciences with a background in cellular immunology
- High motivation and enthusiasm to work independently as well as an active team player
- Strong interest in clinical translation and desire to advance therapy
- Highly organized and strong in independent thinking
- Extensive hands-on training in primary cell culture
- Profound skills in multicolor flow cytometry and cell sorting by FACS
- Experience in viral transduction and genome engineering
- Experience in mass cytometry and big data analysis is a plus
- Excellent English writing, communication and presentation skills, German language not required

## Our offer:

- The next step in your career in the fast growing field of cell and gene therapy
- Attractive key position in a young, open-minded multinational lab with great team spirit
- Ideal balance of independence, creativity and responsibility
- Access to cutting-edge technology (incl. in-house facilities for flow and mass cytometry, next generation sequencing, Good Manufacturing Practice and many more <https://tu-dresden.de/cmcb/technologie-plattform/facilities>)
- Possibility to gain experience in teaching within the international Regenerative Biology and Medicine (RegMed) Master Course at CRTD (optional)
- Possibility to attend in-house German courses for scientists
- Active participation in international conferences
- Flexible and family-friendly working hours
- Childcare through partnerships with day care centers near the Institute at low price
- Company prevention offers including our on-campus fitness center Carus Vital
- Qualification programs through our Graduate Academy <https://tu-dresden.de/ga>
- Job ticket for public transport in Dresden and the surrounding area

Applications of all genders are appreciated. Among candidates of equal aptitude and qualifications, a person with disabilities will be given preference.

We kindly ask you to apply via our **online form** <https://www.uniklinikum-dresden.de/de/jobs-und-karriere/stellenangebote/wissenschaft/postdoctoral-scientist-in-cellular-immunology-t-cell-therapy-f-m-x> until **March 31st, 2022** to make the selection process faster and more effective. Your application should include your CV, relevant certificates/degrees, a summary of your previous scientific experience and statement of your motivation (up to 1 page) and contact information of two referees (if possible). For further information do not hesitate to contact Dr. Anke Fuchs by phone +49(0) 351-458-82125 or preferably via e-mail: [anke.fuchs1@tu-dresden.de](mailto:anke.fuchs1@tu-dresden.de).

## Relevant publications

Wermke M, Kraus S, Ehninger A, Bargou RC, Goebeler ME, ..., [Bornhäuser M](#) et al. Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML. *Blood*. 2021

[Feldmann A](#), Hoffmann A, Bergmann R, Koristka S, Berndt N, Arndt C, ..., [Bachmann M](#). Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. *Oncoimmunology*. 2020 Jul 3;9(1):1785608. doi: 10.1080/2162402X.2020.1785608. PMID: 32923149; PMCID: PMC7458653.

Cartellieri M, [Feldmann A](#), Koristka S, Arndt C, Loff S, ..., [Bachmann M](#). Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. *Blood Cancer J*. 2016;6(8):e458.

Marín Morales, J. M., Münch N, Peter K, ..., [Bornhäuser M](#), [Fuchs, A](#). Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System. *Front. Immunol*. 2019; 10, 38

Koristka S, Kegler A, Bergmann R, Arndt C, [Feldmann A](#), ..., [Bachmann M](#). Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. *J Autoimmun*. 2018;90:116-31

[Theil A \(now Fuchs\)](#), Tuve S, ..., [Bornhäuser M](#). Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. *Cytotherapy*. 2015;17(4):473-86.